Production (Stage)
Xeris Biopharma Holdings, Inc.
XERS
$4.83
-$0.05-1.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 58.44M | 71.62M | 69.40M | 77.57M | 87.35M |
| Total Receivables | 46.33M | 40.42M | 41.14M | 42.44M | 37.41M |
| Inventory | 52.69M | 48.18M | 45.12M | 42.98M | 40.88M |
| Prepaid Expenses | 6.03M | 7.45M | 7.14M | 7.36M | 7.64M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 163.49M | 167.66M | 162.80M | 170.34M | 173.28M |
|
|
|||||
| Total Current Assets | 163.49M | 167.66M | 162.80M | 170.34M | 173.28M |
| Net Property, Plant & Equipment | 27.79M | 28.21M | 28.37M | 28.70M | 28.81M |
| Long-term Investments | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M |
| Goodwill | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M |
| Total Other Intangibles | 96.21M | 98.92M | 101.63M | 104.34M | 107.05M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 5.10M | 5.41M | 5.44M | 5.49M | 4.61M |
| Total Assets | 315.45M | 323.06M | 321.10M | 331.73M | 336.62M |
|
|
|||||
| Total Accounts Payable | 6.35M | 2.29M | 7.45M | 5.80M | 7.09M |
| Total Accrued Expenses | 50.78M | 56.80M | 44.06M | 46.77M | 44.95M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 18.08M | 21.18M | 21.10M | 5.31M | 4.62M |
| Total Finance Division Other Current Liabilities | 19.86M | 20.17M | 18.40M | 17.61M | 16.42M |
| Total Other Current Liabilities | 19.86M | 20.17M | 18.40M | 17.61M | 16.42M |
| Total Current Liabilities | 95.07M | 100.44M | 91.01M | 75.49M | 73.08M |
|
|
|||||
| Total Current Liabilities | 95.07M | 100.44M | 91.01M | 75.49M | 73.08M |
| Long-Term Debt | 217.81M | 217.01M | 216.23M | 230.48M | 229.67M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 32.87M | 33.26M | 33.64M | 34.02M | 34.40M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 4.83M | 1.97M | 8.55M | 11.03M | 8.64M |
| Total Liabilities | 350.58M | 352.68M | 349.43M | 351.02M | 345.79M |
|
|
|||||
| Common Stock & APIC | 645.98M | 642.27M | 638.44M | 631.76M | 626.86M |
| Retained Earnings | -681.08M | -671.86M | -666.75M | -651.01M | -636.01M |
| Treasury Stock & Other | -25.00K | -25.00K | -16.00K | -31.00K | -36.00K |
| Total Common Equity | -35.13M | -29.62M | -28.32M | -19.29M | -9.18M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | -35.13M | -29.62M | -28.32M | -19.29M | -9.18M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | -35.13M | -29.62M | -28.32M | -19.29M | -9.18M |
|
|
|||||